Defence Therapeutics Inc. (DTC.CN) Comparison with companies in other sectors?

Defence Therapeutics Inc. has a share price of 54.73M. You can analyze Defence Therapeutics Inc. (DTC.CN) competitors across different market sectors through stock heatmaps.

What are DTC.CN's NET and operating margins?

Defence Therapeutics Inc. (DTC.CN) operating margin is around 0.00, and net profit margin is approximately 0.00 as of the latest reports.

In what way does DTC.CN's earnings per share (EPS) trend reflect its financial momentum?

Defence Therapeutics Inc. (DTC.CN) EPS is -0.08 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for Defence Therapeutics Inc. is -7.50, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for Defence Therapeutics Inc.?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for Defence Therapeutics Inc. like P/E which is -7.96, P/B which is -134.39, and PEG which is -0.68. Compare them with sector averages to evaluate if the stock is priced fairly.

Defence Therapeutics Inc.

DTC.CN•CNQ

Healthcare

Biotechnology

CA$0.60

CA$0.02(3.45%)

Defence Therapeutics Inc. (DTC.CN) Fundamental Analysis: Financial Health, Valuation, and Key Ratios

Dive into Apple Inc.’s fundamentals including valuation ratios, profitability, efficiency metrics, and financial health. Use this data to assess long-term investment quality and compare it with sector benchmarks.

EPS (TTM)

$-0.08

P/E Ratio

-7.50

ROE

1.30%

Net Margin

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$32.84M

Shares OutstandingTotal number of shares issued

$54.73M

Book Value/ShareNet worth per share

$-0.00

Revenue/ShareAnnual revenue per share

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$-0.08

Net MarginNet income as percentage of revenue

Operating MarginOperating income as percentage of revenue

ROEReturn on shareholders' equity

130.48%

ROAReturn on total assets

-157.04%

ROCEReturn on capital employed

1497.13%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$-0.06

Cash/ShareCash and equivalents per share

$0.04

FCF YieldFree cash flow as percentage of market cap

-9.42%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

Dividend YieldAnnual dividend as percentage of stock price

Financial Ratios Analysis data is not available for DTC.CNFinancial Ratios Analysis details for DTC.CN are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for DTC.CNSector Benchmarking details for DTC.CN are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for Defence Therapeutics Inc. Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of Defence Therapeutics Inc.. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account Defence Therapeutics Inc.'s unique business strengths and challenges.

Key Financial Metrics for Defence Therapeutics Inc.

For Defence Therapeutics Inc., essential financial indicators include EPS -0.08, PE -7.50, and ROE 1.30. These key ratios reveal insights into Defence Therapeutics Inc.'s profitability, valuation, and operational health. Understanding these metrics enables you to compare Defence Therapeutics Inc. with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of Defence Therapeutics Inc.

Metrics like Net Margin - and ROA -157.04% shed light on how well Defence Therapeutics Inc. is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether Defence Therapeutics Inc. can sustain its operations and continue growing in the future.

Valuation and Market Position of Defence Therapeutics Inc.

Using ratios such as P/B Ratio -134.39 and PEG Ratio -0.68, investors can assess whether Defence Therapeutics Inc. is appropriately valued based on its financials and growth potential. These figures, combined with Defence Therapeutics Inc.'s market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for Defence Therapeutics Inc.

Financial health indicators, such as Debt/Equity Ratio -6.34 and Cash Flow $-0.06, provide a snapshot of Defence Therapeutics Inc.'s ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like Defence Therapeutics Inc., is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for Defence Therapeutics Inc.

Investing in Defence Therapeutics Inc. based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at Defence Therapeutics Inc. focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;